Key points of the project
1.We have performed a complete knockout (non-lethal knockout) of over 1,000 target genes in RenMice.
2.We have prepared complete antibodies for over 1,000 targets using RenMice with target KO.
3.We have screened for antibodies with similar affinity to targets across multiple species by using multi-species antigen cross-immunization.
4.We have identified the most effective antibody using in vivo screening for drug efficacy in mice.
5.We have validated the targets and antibody molecules that are effective for mice in large animals with spontaneous diseases, using one to two antibody molecules per target.
6.We plan to submit an antibody IND application for candidate antibody drugs that have been found to be effective in large animals.
"Project Integrum" targets a range of diseases including diabetes, osteoporosis, tumors, autoimmune diseases, and inflammation. Our team has already prepared RenMice with over 1,000 target genes knocked out for this project. We currently have over 600+ targets in the antibody hits stage, and have obtained PCC molecules for 20+ targets. Our goal is to develop drugs for more than 1,000 potential targets over the next three to five years, positioning Biocytogen as a leading source of innovative new drugs, in collaboration with partners from around the world.
Our five antibody technology platforms, derived from RenMice, and the large number of antibody molecules produced in "Project Integrum", will enable us and our partners to explore other drug forms, such as bispecific antibodies, bispecific ADCs, oncolytic viruses, cell therapy, and gene therapy.
To learn more about our work, please visit: https://renmab.com.
Collaboration models and disclosed partners:
“Project Integrum” is an open and collaborative project that aims to develop new drugs through innovative technologies and ideas in flexible cooperation models. We work closely with our partners to drive drug development and foster innovation. By leveraging our collective expertise and resources, we believe that we can accelerate the discovery and development of new drugs to benefit patients around the world.
Under “Project Integrum”, we have established 34 cooperative drug development agreements with 21 domestic and international partners, including companies such as Merck and RemeGen. These partnerships are a testament to our commitment to innovation and collaboration in drug development. We are excited to work with these partners to advance our pipeline and bring new treatments to patients around the world.
Biocytogen Enters into Antibody Agreement with Merck
Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
Biocytogen Enters Agreement with CtM Bio to Co-Develop TCR-Mimic Antibody based Multi-Specific T cell Engagers
AACR 2022: Identifying New Therapeutic Antibodies Using Knockout Mice Expressing Human Immunoglobulin Variable Domain Genes
AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets